-

COTA Announces Strategic Collaboration with Sanofi to Leverage Real-World Data and AI to Accelerate Cancer Trials

NEW YORK--(BUSINESS WIRE)--COTA, a leader in real-world data (RWD) and analytics for oncology, today announced a strategic collaboration with Sanofi to use RWD and artificial intelligence (AI) to increase the speed of oncology trials, including for multiple myeloma. The partnership will be valuable to understand clinical outcomes that may ultimately be beneficial for patients living with cancer.

COTA’s RWD offers critical insights into effective cancer treatment pathways and will provide valuable context on key patient populations.

“Our collaboration with Sanofi has the potential to enable more patients and their families to benefit from breakthrough treatments in an expedited time frame,” said Dr. C.K. Wang, an oncologist and COTA’s chief medical officer. “We are providing high-quality RWD enabled by new AI-based tools to accelerate pharmaceutical research and improve patient care.”

The project will focus on a series of questions pertinent and relevant to multiple myeloma seeking to develop a deeper understanding of the increasingly complex treatment landscape of the disease. Potential results of this partnership could impact and guide future clinical study designs as well as inform the interpretation of results of ongoing and future trials within the context of the current standard of care for multiple myeloma patients.

About COTA, Inc.

Founded by oncologists, COTA is committed to creating a precise, patient-first approach to cancer care through the use of real-world data. The company leverages technology-supported data abstraction methods to make sense of complex, fragmented patient data from the real world. Offering the highest quality oncology real-world data from leading academic and community-based cancer centers and an advanced analytics platform, COTA partners with leading life sciences companies, providers, and payers to ensure that everyone touched by cancer has a clear path to the right care. To learn more about COTA and how to fast-track improvements in cancer care and treatment with comprehensive and diverse real-world data and analytics, visit cotahealthcare.com.

Contacts

Press Contact
Dori Young
Email: Dori@12080group.com

COTA, Inc.


Release Versions

Contacts

Press Contact
Dori Young
Email: Dori@12080group.com

More News From COTA, Inc.

COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics

NEW YORK--(BUSINESS WIRE)--COTA Inc., a leader in real-world data (RWD) and analytics for oncology, announces a new partnership with leading precision oncology company Guardant Health Inc. (Nasdaq: GH) that will allow biopharmaceutical researchers to access the combined resources of COTA’s research-grade electronic health record (EHR) data from academic and community care centers and Guardant’s clinicogenomic testing data to accelerate the development of new cancer therapies. Using the extensiv...

Research from COTA and leading global cancer center demonstrate how Real-World Data can fill cancer care gaps for older patients

NEW YORK--(BUSINESS WIRE)--COTA, Inc., a leader in real-world data (RWD) and analytics for oncology, and Memorial Sloan Kettering Cancer Center (MSK) today announced that data from two Diffuse Large B-Cell Lymphoma (DLBCL) studies in older patients will be presented at the upcoming 66th American Society of Hematology Annual Meeting (ASH), held December 7-10, 2024, in San Diego and virtually. The joint research explores the implication of treatment urgency and end-of-life care patterns for older...

COTA and Texas Oncology Collaborate to Advance AI-Enabled Precision Medicine

NEW YORK--(BUSINESS WIRE)--COTA, Inc., in collaboration with Texas Oncology’s Precision Health Informatics, LLC (PHI), announces an innovative collaboration aimed at revolutionizing precision medicine across Texas Oncology’s community cancer centers. Leveraging COTA’s AI-powered curation engine, CAILIN™, this collaboration will transform fragmented healthcare data into actionable insights. Unlocking Insights from Electronic Health Records (EHRs) Electronic health records contain a comprehensive...
Back to Newsroom